Organization
Humacyte
9 clinical trials
Clinical trial
A Phase 3 Randomized Study to Compare the Efficacy and Safety of the Humacyte Human Acellular Vessel (HAV) With That of an Autogenous Arteriovenous Fistula (AVF) in Female Patients With End-Stage Renal Disease Requiring HemodialysisStatus: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 2 Assessment of Humacyte's Human Acellular Vessel in Patients Needing Vascular Access for DialysisStatus: Completed, Estimated PCD: 2021-05-15
Clinical trial
An Observational Multicenter Study to Evaluate the Safety and Efficacy of Humacyte's Human Acellular Vessel in a Real World Setting for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular TraumaStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY)Status: Completed, Estimated PCD: 2022-09-01
Clinical trial
A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vessel for Use as a Vascular Prosthesis for Femoro-Popliteal Bypass in Patients With Peripheral Arterial DiseaseStatus: Completed, Estimated PCD: 2020-12-01
Clinical trial
A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft as an Above-Knee Femoro-Popliteal Bypass Graft in Patients With Peripheral Arterial DiseaseStatus: Active (not recruiting), Estimated PCD: 2016-05-30
Clinical trial
A Phase 2/3 Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients With Life or Limb-threatening Vascular TraumaStatus: Active (not recruiting), Estimated PCD: 2027-09-01
Clinical trial
A Phase 3 Study to Compare the Efficacy and Safety of Humacyte's Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-09-01